Clinical trials
Osteonecrosis trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2012 | 4 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 6 |
| 2018 | 1 |
| 2022 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 26 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| BG Trauma Center Ludwigshafen | 2 |
| AO Clinical Investigation and Publishing Documentation | 1 |
| Assiut University | 1 |
| Biomatlante | 1 |
| Central Hospital, Nancy, France | 1 |
| Chinese PLA General Hospital | 1 |
| Corin | 1 |
| Federal University of Bahia | 1 |
| Halton, Jacqueline, M.D. | 1 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Osteonecrosis | 26 |
| Osteoarthritis | 7 |
| Femur Head Necrosis | 3 |
| Arthritis, Rheumatoid | 2 |
| Infertility | 2 |
| Osteochondritis Dissecans | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Anemia, Sickle Cell | 1 |
| Arthritis | 1 |
| Bisphosphonate-Associated Osteonecrosis of the Jaw | 1 |
Trials
Showing 51 to 26 of 26. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.